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Stroke is a long-term disability and one of the leading causes of death. However, no successful therapeutic intervention is
available for the majority of stroke patients. In this study, we explored a traditional Chinese medicine Baifuzi (Typhonium
giganteum Engl.). We show, at ﬁrst, that the ethanol extract of Baifuzi exerts neuroprotective effects against brain damage
induced by transient global or focal cerebral ischemia in rats and mice. Second, the extract activated large-conductance Ca
2þ-
activated K
þ channel (BKCa) channels, and BKCa channel blockade suppressed the neuroprotection of the extract, suggesting
thattheBKCaisthemolecular targetofBaifuzi.Third,Baifuzicerebroside(Baifuzi-CB), puriﬁed fromitsethanolextract,activated
BKCa channels in a manner similar to that of the extract. Fourth, the stress axis hormone-regulated exon (STREX) domain of the
BKCa channel directly interacted with Baifuzi-CB, and its deletion suppressed channel activation by Baifuzi-CB. These results
indicate that Baifuzi-CB activated the BKCa channel through its direct interaction with the STREX domain of the channel and
suggests that Baifuzi-CB merits exploration as a potential therapeutic agent for treating brain ischemia.
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Stroke is a devastating condition that annually affects 15
million people worldwide, and is the leading cause of adult
disability in industrialized countries.
1 Although there has been
progress in our understanding of the pathophysiology of
stroke during the past few decades, stroke continues to pose
major therapeutic challenges, both to neuroscientists and to
clinicians.
2 For example, a large number of neuroprotective
agents have been shown to successfully reduce infarct size in
animal models of stroke, but they have failed to demonstrate
efﬁcacy in phase III clinical trials in humans.
3 To date, no
successful therapeutic interventions are available for the
majority of stroke patients.
1,3 The intravenous recombinant
tissue plasminogen activator (rt-PA) is the only drug therapy
available for thrombolytic treatment of stroke in the United
States, Canada and Europe. However, the requirement to
exclude hemorrhagic stroke and the restriction to use within
3h of the onset of symptoms limit rt-PA therapy to only B2%
of all stroke patients.
1 Therefore, there is an urgent need for
new therapeutic options for the treatment of stroke.
One of the options that might offer fertile ground for modern
drugdevelopmentistraditionalmedicines,becausetraditional
medicines, such as traditional Chinese medicine (TCM), have
long time since documented the effects of many natural
products on humans, and extensive human experience can
provide some degree of comfort with regard to their safety.
4
Clinical application of artemisinin, triptolide, celastrol, capsai-
cin and curcumin has demonstrated the power and promise of
turning traditional medicines into modern drugs. One of the
most recent examples is veregen, an extract of green tea
leaves, whichwasapprovedin2006bytheUS FoodandDrug
Administration as a new drug to treat perianal and genital
condyloma.
5 As a matter of fact, more than half of the
pharmaceutical drugs are either natural products or their
derivatives.
6
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(Chinese name: Baifuzi), as a TCM, has been recorded in
Chinese pharmacopeia and used for the treatment of brain
stroke for a long time.
7 However, unlike industrially manu-
factured pharmacological drugs used in Western medi-
cine, its active components and molecular targets have not
been speciﬁed. Obviously, identiﬁcation of its effects on well-
deﬁned molecular targets and the subsequent identiﬁcation of
its activecomponent(s) underlying theseeffects are important
for the evaluation of its therapeutic efﬁcacy. Brain ischemia
begins with energy depletion, followed by the disruption of ion
homeostasis, membrane depolarization, excessive neuro-
transmitter (glutamate) release and elevation of intracellular
calcium, all of which initiate a neurotoxic cascade that results
in neurodegeneration and death of ischemic neurons.
8,9 The
large-conductance Ca
2þ-activated K
þ (BKCa) channels are
widely expressed in the brain
10 and are preferentially located
at glutamatergic synaptic terminals.
11,12 They react to either
increases in intracellular Ca
2þ or membrane depolarization
byincreasingK
þ efﬂux.Thus,theyfunctionasan‘emergency
break’ to limit Ca
2þ inﬂux for regulating synaptic transmission
under conditions of enhanced neuronal excitability.
13 It has
been shown that activation of BKCa channels in ischemic cells
by BKCa channel openers could minimize neuronal depolar-
ization, limit accumulation of potentially pathological levels of
Ca
2þ from a number of potential sources, reduce neuro-
transmitter release and signiﬁcantly attenuate infarct growth
during ischemic stroke in animal models.
14,15 In addition,
blockade of BKCa channels enhanced cell damage in
organotypical slice cultures after oxygen and glucose depri-
vation.
16 In this study, we show that the ethanol extract of
Baifuzi (e-Baifuzi) shows signiﬁcant neuronal protective
activity in the rat and mice model of ischemic stroke. Second,
we show that the BKCa channel is the molecular target of the
ethanol extract. Third, we identiﬁed that Baifuzi cerebroside
(Baifuzi-CB) is the active component of Baifuzi in activating
the BKCa channel. Finally, we show that the stress axis
hormone-regulated exon (STREX) domain of the BKCa
channel, a 59-amino-acid splice insertion located in the
cytoplasmic side of the channel, is required for the activation
of the BKCa channel by Baifuzi-CB, probably due to direct
interaction between Baifuzi-CB and the STREX domain.
Results
e-Baifuzi protects ischemia-induced brain injury
e-Baifuzi against ischemia-induced neuronal cell
death. Transient global ischemia leads to a dramatic loss of
neurons in the CA1 region of the hippocampus.
17,18
Therefore, we examined whether e-Baifuzi has
neuroprotective roles in the CA1 region in the rat model of
transient global ischemia, which was made by 20min 4-
vessel occlusion (4VO). In the CA1 region of the ischemic
hemisphere, the number of pyramidal neurons on the eighth
day post-4VO was o50% of the control (2VO rats, n¼8,
Po0.01; Figures 1a and b). Surprisingly, a single injection of
e-Baifuzi (5 or 50mg/kg) at 1h post-4VO signiﬁcantly
attenuated neuronal loss in a dose-dependent manner
(versus vehicle-treated 4VO rats, n¼8, Po0.01), although
no neuroprotective effect was observed at a dosage of 1mg/
kg (P40.05). In contrast, the administration of e-Baifuzi at a
dosage of 5mg/kg did not affect the number of pyramidal
neurons in 2VO rats (n¼8, P40.05). Furthermore, the
administration of e-Baifuzi (5mg/kg) even at 4–8h post-4VO
also signiﬁcantly reduced ischemia-induced neuronal loss
(versus vehicle-treated 4VO rats, n¼8, Po0.01; Figure 1c),
whereas it could not protect neuronal cells when administered
at 24h post-4VO (n¼8, P40.05). These results suggested
that e-Baifuzi could protect the brain from transient global
cerebral ischemia and that its therapeutic time window may
last up to 8h after the onset of ischemia.
e-Baifuzi improves ischemia-induced deﬁcits in spatial
memory. Neuronal damage induced by transient global
ischemia is accompanied by severe impairments in
performance on hippocampally dependent spatial learning
tasks.
19 To investigate whether e-Baifuzi could improve the
behavioral disorder induced by transient global cerebral
ischemia, we evaluated its effects on the performance of rats
in a Morris water maze test. Results showed that rats
subjected to 20min global cerebral ischemia (4VO)
signiﬁcantly extended the escape latency to the hidden
platform compared with 2VO rats (n¼8, Po0.01; Figure 1d),
whereas the swimming speed was not detectably different
between them (data not shown). In agreement with its
neuroprotection, e-Baifuzi (5mg/kg) reduced ischemia-
induced prolongation of the escape latency when
administered between 1 and 8h post-4VO (versus vehicle-
treated 4VO rats, n¼8, Po0.01). In contrast, it did not affect
the escape latency of 2VO rats at a dosage of 5mg/kg (n¼8,
P40.05). Thus, e-Baifuzi could improve spatial memory
impairment induced by global cerebral ischemia.
e-Baifuzi reduces MCAO-produced cerebral infarction. To
determine the effect of e-Baifuzi against focal cerebral
ischemia-induced injury, we used a mouse model of middle
cerebral artery occlusion (MCAO) by the intraluminal ﬁlament
insertion technique. Infarct size was measured at 24h of
reperfusion as described previously.
20 As shown in Figure 2a
and b, a single injection of e-Baifuzi (5mg/kg) at 1h post-
MCAO remarkably reduced the hemispheric infarct, from
42±2% in vehicle (saline)-injected MCAO mice (n¼10) to
19±5% in e-Baifuzi-injected MCAO mice (n¼11, Po0.01),
indicating that e-Baifuzi could reduce cerebral infarct induced
by focal ischemia-induced damage.
e-Baifuzi protects the brain from ischemic injury
through activation of BKCa channels
e-Baifuzi activates BKCa channels. The above study
conﬁrmed the protective role of e-Baifuzi in ischemic injury.
As BKCa channels have been shown to have an important
role in ischemic stroke,
14,15 we explored whether the BKCa
channel is a potential target for the effect of e-Baifuzi. Whole-
cell conﬁguration was used to investigate the effect of
e-Baifuzi on the whole-cell currents of BKCa channels
expressed in CHO cells. All test experiments (n¼28)
showed an increase in current amplitude with the
application of e-Baifuzi. Figure 3a clearly shows increases
in whole-cell BKCa channel currents from the same cell in
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Cell Death and Diseaseresponse to e-Baifuzi at a concentration of 0.45mg/ml. At a
voltage of þ100mV, 0.45mg/mle - Baifuzi increased the
current two and threefold at an intracellular Ca
2þ
concentration of 0.1 and 1mM, respectively (Figure 3b). At
the single channel level, e-Baifuzi increased the single
channel open probability (Po) from 2.1±0.9% of control
(n¼11) to 18.4±6.3% in the presence of 0.45mg/mle - Baifuzi
(n¼8) without affecting its amplitude (Figure 3c and d).
These results indicated that e-Baifuzi could activate the BKCa
channel and implied that the BKCa channel is the molecular
target of Baifuzi.
e-Baifuzi reduces presynaptic glutamate release. Excessive
glutamate release and subsequent excitotoxicity are major
pathological factors leading to neurodegeneration and death
of ischemic neurons.
8,21 Previous studies have reported that
BKCa channels located at glutamatergic presynaptic
terminals
12 regulate presynaptic Ca
2þ entry,
10 which in
turn regulates presynaptic glutamate release.
11 Therefore,
we investigated the effect of e-Baifuzi on presynaptic
glutamate release. First, the excitatory postsynaptic
potential (EPSP) slopes in the presence of e-Baifuzi
(0.45mg/ml) were consistently less than those in its absence
Figure 1 Effects of e-Baifuzi on global cerebral ischemia. (a) Representative sections in 2VO and 4VO rats treated with vehicle or e-Baifuzi (0, 1, 5 and 50mg/kg) at 1h
post-4VO. (b) Bar graphs represent the number of surviving pyramidal neurons of hippocampal CA1 in 2VO (open bars) and 4VO rats (hatched bars). Histological changes
inischemichippocampalCA1wereassessedontheeighthdaypost-4VO.(c)Timewindowofe-Baifuzineuroprotectionpost-4VO.Asingleinjection(i.p.)ofe-Baifuzi(5mg/kg)
is administered at 1, 4, 8 or 24h post-4VO. *Po0.05, **Po0.01. (d) Effects of e-Baifuzi on 4VO-impaired special memory. The Morris water maze test was carried out at
3–7dayspost-4VO.BargraphsrepresenttheresultsofescapelatencytoreachthehiddenplatformontheﬁfthdayofMorriswatermazetraining.Itmustbenotedthatasingle
administration of e-Baifuzi within 1–8h post-4VO decreases the ischemia-induced death of neuronal cells and prolongation of latency. so, stratum oriens; sp, stratum
pyramidal; sr, stratum radiatum; BF, e-Baifuzi.
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Cell Death and Disease(Figure 4a, Po0.05; n¼10 slices per 5 rats). In addition, the
reduction of the EPSP slope completely recovered within
10min after e-Baifuzi washout (n¼12 slices per 6 rats;
Figure 4b), indicating that e-Baifuzi reversibly suppresses
synaptic transmission. Second, paired-pulse facilitation
(PPF), a sensitive indicator of presynaptic glutamate
release, was measured by delivering two successive stimuli
with 25–150 interpulse intervals (IPIs). Compared with that
before the addition of e-Baifuzi, the paired-pulse ratio (PPR)
at 50–75 IPI was markedly increased after addition of
e-Baifuzi (0.45mg/ml) (Po0.05, n¼15 slices per 7 rats;
Figure 4c). Furthermore, we measured the synaptically
induced glial depolarization (SIGD), an indicator of the
amount of presynaptic glutamate release,
22 in the presence
of CNQX (10mM)/AP5 (50mM) (see the ‘Materials and
Methods’ section). Consistent with the result of PPF, the
area of SIGD was signiﬁcantly reduced by perfusion of e-
Baifuzi (0.45mg/ml) (Po0.05, n¼12 slices per 6 mice), and
could be recovered after the washout of e-Baifuzi (Figure 4d).
Thus, e-Baifuzi could reversibly reduce presynaptic
glutamate release, which in turn might protect the brain
from the excitotoxicity of excessive glutamate release.
Blockade of BKCa channels abolishes the neuroprotection
and glutamate release induced by e-Baifuzi. If the BKCa
channel is the molecular target, then its blocker should
suppress the neuroprotective effect of e-Baifuzi. To deter-
mine whether the neuroprotection of e-Baifuzi is associated
with BKCa channel activation, charybdotoxin (CTX, 400nM)
was administered (i.v.c) for 30min before the injection of
e-Baifuzi (5mg/kg) at 1h post-4VO. Blockade of the BKCa
channel by CTX pretreatment signiﬁcantly prevented the
neuroprotection of e-Baifuzi (Figure 5a, Po0.01, n¼8),
whereas CTX alone had no signiﬁcant effect on either 2VO
or 4VO rats in comparison with the corresponding vehicle-
treated control groups. As CTX is a speciﬁc blocker of
the BKCa channel, the result strongly suggests that the
BKCa channel is the molecular target of e-Baifuzi for
its neuroprotective effect. Furthermore, we found that ad-
ministration of 100nM CTX could prevent e-Baifuzi from
reducing the area of SIGD (Po0.05, n¼12 slices per 6 rats;
Figure 5b). These results strongly suggest that e-Baifuzi
protects ischemia-induced brain injury by opening BKCa
channels to decrease presynaptic glutamate release, and
gives further evidence that the BKCa channel is the molecular
target of Baifuzi.
Baifuzi-CB is the major active ingredient
The above studies indicated that e-Baifuzi had a signiﬁcant
neuroprotective effect on the ischemic brain through activa-
tion of BKCa channels. This result prompted us to seek the
active ingredient(s) of Baifuzi. We isolated Baifuzi-CB from
e-Baifuzi,
23 which was veriﬁed by
1H and
13C NMR spectra
(Supplementary Figures 1b and c). They appeared as one
point on a normal silica gel thin layer chromatography (TLC)
plate (Supplementary Figure 1a). Although phytochemical
studies have shown that Baifuzi contains several other
chemicals, including amino acids, fatty acids, choline, uracil,
daucosterol and dipalmin,
23 we began our studies by focusing
on Baifuzi-CB, because our previous study showed that
sulfatide, a kind of cerebroside, can potently activate BKCa
channels.
24 In whole-cell patch-clamp recordings, Baifuzi-CB
dose-dependently increased BKCa channel currents. Intra-
cellular application of 10mM Baifuzi-CB increased the relative
BKCa channel current (I/Io) from 0.80±0.06 of control to
Figure 2 Effects of e-Baifuzi on brain infarct after MCAO. (a) Representative
section of vehicle-treated sham, vehicle-treated MCAO and e-Baifuzi (5mg/kg)-
treatedMCAOrats.(b)Bargraphsrepresentthemeaninfarctvolumepercentagein
sham-op (open bars) and MCAO-mice (hatched bars) treated with vehicel or
e-Baifuzi (5mg/kg) at 1h post-MCAO. **Po0.01
Figure 3 e-Baifuzi activates BKCa channels. (a) Representative current trace of
whole-cell BKCa channel current before (control) and after 10min of extracellular
applicationof0.45mg/mle - Baifuzi. Thecurrentwas activatedbyrectangularvoltage
steps from  80 to þ100mV for 200ms with 10mV increment. (b) Statistics on
ratiovalues(I/Io)of thewhole-cellBKCacurrentbefore(Io)andafter(I)applicationof
0.45mg/mle - Baifuzi at þ100mV in the presence of 0.1 and 1mM intracellular
Ca
2þ, respectively.(c) Representative single channel recordings of the BKCa
channels in excised inside-out conﬁguration at þ50mV. Channel openings are
shownasan upwarddeﬂection.Arrowsindicatethelevelthatallthechannelsare at
their closed state. (d) Statistical data for open probability (Po) of the single BKCa
channels in the presence of 0.45mg/mle - Baifuzi
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Cell Death and Disease3.32±0.88 (Figure 6a). On the other hand, extracellular
application of 10mM Baifuzi-CB increased the relative BKCa
channel current from 0.70±0.07 of control to 1.31±0.15
(Figure 6b), suggesting that the action site of Baifuzi-CB is
easier to accessfromthe intracellular side.To examinewhether
the activation of BKCa channels by Baifuzi-CB was due to some
diffusible intracellular signal molecules, the effect of Baifuzi-CB
on BKCa channels was further examined at a single channel
level in excised outside-out patches. As shown in Figure 6c,
application of 10mM Baifuzi-CB to the outside-out patch
enhanced Po from 3.1±1.7% to 12.0±3.2%. Activation of
BKCa channels by Baifuzi-CB in patches excised from the cell
membranestronglysuggeststhattheiractionsarenotmediated
by diffusible intracellular signal molecules. On the basis of the
amount of Baifuzi-CB puriﬁed from e-Baifuzi, it is calculated
that e-Baifuzi contains 0.87% of Baifuzi-CB. Thus, 0.45mg/mlo f
Figure 4 e-Baifuzi reduces presynaptic glutamate release. (a) Stimulus–response curve, in which the EPSP slope were evoked by stimulating the Schaffer collaterale-
CA1 path with a current from 0.1 to 1.0mA in the absence and presence of e-Baifuzi (0.45mg/ml), was constructed by plotting the EPSP slope against stimulus intensity
(0.1–1.0mA). (b) Reversible inhibition of the EPSP slope by a transient application of e-Baifuzi (0.45mg/ml). Horizontal hatched bar indicates the duration of e-Baifuzi
application. (c)Effectofe-Baifuzionpresynapticglutamaterelease.Paired-pulsesfacilitation(PPF)wasevokedbeforeandaftertheadditionofe-Baifuzi(0.45mg/ml).Paired-
pulses ratios (PPR) are plotted against various IPIs. (d) Sample traces of SIGD were obtained just before, during and after the application of e-Baifuzi (0.45mg/ml).
Hippocampal slices were stained with RH155, a voltage-sensitive dye. SIGD: synaptically induced glial depolarization. Horizontal hatched bar indicates the duration of
e-Baifuzi application. **Po0.01
Figure 5 Effect of e-Baifuzi on neuroprotection and glutamate release in the presence of BKCa channel blocker. (a) Role of CTX in e-Baifuzi neuroprotection. CTX at
400nM was infused into the cereboventricle (i.c.v.) at 30min before the injection of e-Baifuzi (5mg/kg). Bar graphs represent the number of surviving pyramidal neurons of
hippocampal CA1 in 2VO (open bars) and 4VO rats (hatched bars). **Po0.01. (b) Effect of e-Baifuzi on the SIGD area in the presence of 100nM CTX
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Cell Death and Diseasee-Baifuzi corresponds to 5.1mMo fBaifuzi-CB (MW B720
Dalton). Comparing Figure 3a and 6b, the channel activated by
10mM Baifuzi-CB is at the same level as that of 0.45mg/mle -
Baifuzi,indicatingthatBaifuzi-CBisthemajoractivecomponent
responsible for the activation of the BKCa channel.
Molecular mechanism of BKCa channel activation by
Baifuzi-CB
STREX is required for BKCa channel activation by Baifuzi-
CB. It has been shown in our previous studies that STREX is
important for activation of BKCa channels by lipid-soluble
chemicals.
24,25 Besides, it has been demonstrated that
inclusion of the STREX exon facilitates voltage- and Ca
2þ-
dependent activation of BKCa channels.
26 To test whether
STREX contributes to the activation of the BKCa channel by
Baifuzi-CB, we studied its effect on the STREX-deleted
mutant of the channel. Both intracellularly (1mM, Figure 7)
and extracellularly (10mM, Figure 6b) applied Baifuzi-CB
signiﬁcantly increased whole-cell current for wild-type BKCa
channels. The relative whole-cell current was increased
from 0.80±0.06 of control to 1.57±0.28 in the presence
of 1mM Baifuzi-CB applied intracellularly (Figure 7b),
whereas extracellularly applied Baifuzi-CB (10mM) increased
the current from 0.70±0.06 of control to 1.31±0.15
(Figure 6b). In contrast, the STREX-deleted mutant BKCa
channel could not be activated by Baifuzi-CB, whether it
was applied intracellularly (Figure 7b) or extracellularly
(Supplementary Figure 2), indicating that STREX is
required for BKCa channel activation by Baifuzi-CB.
Interaction between Baifuzi-CB and STREX. We investi-
gated the manner in which Baifuzi-CB is sensed by STREX,
which is located at the cytoplasmic side, to activate the
BKCa channel. A simple explanation may be that STREX
interacts directly with Baifuzi-CB and consequently conveys
the signal to gate the channel. To test whether the STREX
domain is sufﬁcient for Baifuzi-CB binding, we performed
a protein lipid overlay (PLO) assay. No interaction was
detected between STREX and POPE (1-Palmitoyl-2-Oleoyl-
sn-Glycero-3-Phosphoethanolamine), 1-Palmitoyl-2-Oleoyl-
sn-Glycero-3-[Phospho-rac-(1-glycerol (POPG) or DL-a-
Phosphatidylcholine Dipalmitoyl (DPPC). In contrast, the
STREX domain of the BKCa channel could interact with both
Figure 6 Effect of intracellularly and extracellularly applied Baifuzi-CB on BKCa
channels.(a) Left:Representativecurrenttracesbefore(control)andafter10min of
intracellularapplicationof1mMBaifuzi-CB([CB]i).Right:StatisticsonI/Ioatdifferent
concentrations of Baifuzi-CB at þ100mV. (b) Representative current traces (left)
andstatisticalsummaryonI/Io(right)forwhole-cellBKCachannelcurrentbeforeand
after 10min of extracellular application of 10mM Baifuzi-CB ([CB]o). (c)
Representative single BKCa channel current traces at þ10mV (left) and statistical
summary on its Po (right) with and without Baifuzi-CB in the outside-out
conﬁguration. Asterisk indicates signiﬁcant differences between control and
Baifuzi-CB-treated BKCa current. *Po0.05; CB, Baifuzi-CB
Figure 7 STREX is required for BKCa channel activation by Baifuzi-CB. (a) Representative current traces for wild-type (left) and STREX-deleted (right) BKCa
channels in control and in the presence of 1mM Baifuzi-CB applied intracellularly ([CB]i). (b) Statistics on I/Io for wild-type and STREX-deleted BKCa channels at þ100mV.
CB, Baifuzi-CB
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manner (Figure 8a), indicating that Baifuzi-CB can bind to
the BKCa channel through its STREX domain. Interestingly,
Baifuzi-CB and e-Baifuzi, which can bind to STREX, could
activate the channel (Figure 3 and Figure 6), whereas POPE,
POPG and DPPC, which cannot bind to STREX could not
activate the channel (Figures 8b and d). These results
strongly suggest that the interaction with the STREX domain
is critical for BKCa channel activation by Baifuzi-CB. If this is
true, then the overexpression of STREX fragments will
interrupt the interaction between Baifuzi-CB and the STREX
domain of the channel, which might subsequently suppress
the ability of Baifuzi-CB to activate the channel. To conﬁrm
this hypothesis, the STREX fragment was overexpressed
with BKCa channels (BKCa/STREX¼1:2, q/q). This
overexpression signiﬁcantly inhibited the ability of Baifuzi-
CB to activate the channel (Figure 8c and d). This result
further conﬁrmed that the BKCa channel activated by Baifuzi-
CB is through its interaction with the STREX domain of the
channel.
Discussion
In this study, we show that e-Baifuzi protects ischemia-
induced brain injury through activation of BKCa channels,
whichinturncouldreducetheexcitotoxicglutamatereleaseat
the condition of brain ischemia. This conclusion is supported
by the following four results: (1) e-Baifuzi protected ischemia-
induced brain injury in a dose-dependent manner when
administered after global or focal cerebral ischemia in rats
and mice. (2) e-Baifuzi activated the BKCa channel by
increasing its Po without affecting its amplitude. (3) The
neuroprotective effect ofe-Baifuzicouldbesuppressedbythe
speciﬁc blocker of BKCa channels. (4) e-Baifuzi suppressed
presynaptic glutamate release through the activation of BKCa
channels in hippocampal slices.
Furthermore, we propose that the BKCa channel activated
by Baifuzi-CB is through the interaction between Baifuzi-CB
and the STREX domain of the BKCa channel according to the
following pieces of evidence: (1) PLO assay indicated the
direct interaction between Baifuzi-CB and the STREX
domain; (2) the STREX domain is required for activation of
the BKCa channel by Baifuzi-CB, indicating that the interaction
between the STREX domain and Baifuzi-CB is critical for
channel activation. This is in accordance with the result that
intracellular application of Baifuzi-CB is more effective than
that applied extracellularly. (3) Lipid molecules that did not
interact with the STREX domain did not activate the BKCa
channel. (4) Overexpression of STREX fragments suppresses
the ability of Baifuzi-CB to activate the BKCa channel.
Figure 8 Direct interaction between Baifuzi-CB and the STREX domain of the BKCa channel. (a) The ability of STREX to bind various lipid-soluble materials. The
concentrationofthelipid-solublematerialwasincreasedfromrighttoleftandspottedontonitrocellulosemembranes.(b)EffectofPOPE,POPGandDPPConBKCachannels
at þ20mV. (c) Intracellularly applied Baifuzi-CB (1mM) on the single wild-type BKCa channels (left) and on the channels with an overexpression of STREX fragments
(BKCa/STREX¼1:2, q/q) (right) at þ10mV. (d) Statistical summary for the experiment in panels b and c
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Cell Death and DiseaseMany BKCa channel modulators have been reported to
prevent neuronal degeneration after ischemia in preclinical
studies. However, there is no approval of a single BKCa
channel modulator for clinical use so far. For example, BMS-
204352, one of the potent BKCa channel activators described
to prevent neuronal degeneration after ischemia, has failed to
improve the clinical outcome in patients affected by stroke.
27
In this study, we demonstrated that Baifuzi could effectively
reduce brain damage in both focal and global ischemia. We
are aware that there is no guarantee that Baifuzi will be
effective in the clinical treatment of stroke. However, the
following reasons may suggest its potential of being regarded
as a therapeutic agent: (1) Baifuzi has been effectively used
for the treatment of brain stroke for a long time in China
7. (2)
Cerebrosides are rich in the brain, implying that Baifuzi-CB
mayhavea target-speciﬁceffectonneurons.(3)Asananalog
of membrane cerebroside, Baifuzi-CB may be transported by
the endogenous transport machinery to target cells to fulﬁll
its action.
Lipid–protein interactions are of fundamental importance,
as they partly determine the structures of integral membrane
proteins and their activities.
28 Lipid regulation of channels has
beendemonstratedforNMDAreceptorchannels,
29,30TRAAK
channels,
31 transient receptor potential channels,
32 inward
rectiﬁerK
þ channels,
33Ca
2þ channels,
34voltage-dependent
K
þ channels,
35 BKCa channels
36,37 and Twik-related K
þ
channels.
38 The KcsA potassium channel only opens if the
membrane contains a small amount of an anionic lipid, and
lipid association has actually been resolved in the crystal
structure of KcsA K
þ channels.
39 Therefore, it is not
surprising that Baifuzi-CB can activate BKCa channels. In
agreement with this result, we have previously found that
sulfatide, a kind of cerebroside, can potently activate BKCa
channels.
24 In this study, we found that the BKCa channel can
be activated by Baifuzi-CB even at the excised membrane,
implying that channel activation was not due to some
intracellular diffusible signals. Besides, Baifuzi-CB could not
increase at the intracellular Ca
2þ level in hippocampal
neurons (data not shown), suggesting that BKCa channel
activation is not due to an increase in intracellular Ca
2þ
concentration. Then, how does Baifuzi-CB activate the
channel? There are at least three possibilities, which are not
exclusive with each other: (1) The STREX domain of the BKCa
channel is attracted toward the plasma membrane because of
the direct interaction with Baifuzi-CB, leading to a stabilization
oftheopenstate.Thisissimilartowhathasbeenproposedfor
the PI(4,5)P2-dependent gating of inward-rectiﬁer K
þ chan-
nels.
40 (2) Baifuzi-CB alters the thickness of the membrane,
and thus makes the BKCa channel easy to open. This
mechanism has been shown for BKCa channel activation by
phosphatidylcholines (PCs) of varying chain lengths.
41 (3)
Baifuzi-CB may create stress in the membrane because of its
large head group, as we reported previously for the BKCa
channel activated by membrane stress created with amphi-
paths.
25Obviously,furtherstudiesarerequiredtojudgewhich
one or their combinations is correct.
In both global and focal ischemia, restriction of blood ﬂow to
the brain limits the delivery of oxygen and glucose to neurons,
causing energy depletion. This is followed by a cascade
of neurochemical events, including disruption of ion
homeostasis,excessivereleaseofglutamate,overloadofintracel-
lular Ca
2þ, release of free radicals, inﬂammatory changes
and ﬁnally cell death of neurons, glia and endothelial cells.
9,42
These injury cascades are interconnected in complex ways,
as one event in the cascade can cause or can be caused by
multiple other events, and cells suffering from different
severity levels of ischemia may undergo different chemical
processes.Onthe otherhand, AKThasbeen showntohave a
prominent part in signaling networks that result in the
modulation of cellular proliferation, apoptosis and survival.
Recently, activation of AKT has been demonstrated to be
important in neuronal survival after cerebral ischemia.
43–46
The neuroprotective effects of nerve growth factor, osteo-
pontin, erythropoietin, as well as preconditioning and post-
conditioning to reduce ischemia-induced brain injury, are
mediated by AKT
47–50. In our study, we demonstrated that
Baifuzi could activate the BKCa channel and reduce the
release of glutamate, which is responsible for the neuropro-
tective effect of Baifuzi. Therefore, it would be very interesting
to study whether the AKT pathway is involved in the effect of
Baifuzi on brain ischemia.
In summary, we demonstrated that e-Baifuzi provided
signiﬁcant neuroprotection, not only in protecting neurons
against cell death but also in promoting behavioral recovery in
the animal model of stroke. We identiﬁed the BKCa channel as
a molecular target for the therapeutic action of Baifuzi, and
that Baifuzi-CB is the active component that effectively
activates BKCa channels. Through BKCa channel activation,
e-Baifuzi limited glutamate release, which is involved in
excitotoxicity during ischemic damage. These data provide
evidence that e-Baifuzi attenuates ischemia-induced neuro-
nal damage by enhancing the activation of BKCa channels. Its
neuronal protective effect provides pharmacological rationale
forthetraditionaluseofBaifuziinstroke.Asthenaturalsource
of Baifuzi, the medicinal tubers of T. giganteum Engl., has a
long history in Chinese traditional medicine, it is hoped that
Baifuzi-CB will be a well tolerated, promising therapeutic
candidate for the treatment of ischemic brain stroke and other
forms of neuronal damage.
Materials and Methods
Extraction and isolation. Tubers of Baifuzi were collected from Yuxian
County (Henan Province, China). The dried material was powdered and then
extracted with 95% ethanol for several days with shaking. The extract was
concentrated to yield e-Baifuzi.e - Baifuzi was chromatographed on silica gel, then
on ODS to afford Baifuzi-CB, which was conﬁrmed to be a mixture of cerebrosides
on the basis of
1H and
13C NMR spectra (Supplementary Figure 1b and c). TLC
experiment indicated that Baifuzi-CB is one of the major spots of e-Baifuzi
(Supplementary Figure 1a). The detailed process was described in our previous
paper.
23
Experimental animals. Male Sprague–Dawley rats (weighing 200–250g,
Oriental Bio Service Inc., Nanjing, China) and male mice (weighing 25–30g,
OrientalBioServiceInc.)wereusedthroughoutthestudy.Animalswerehousedina
light-controlledroomundera12hlight–darkcyclestartingat0700hoursandkeptat
251C. They were given unrestricted access to food and water. All procedures were
in accordance with the guidelines of the Institute for Laboratory Animal Research of
the Nanjing Medical University.
Preparation of the global brain ischemia model. We used a 4VO
method for transient global ischemia as described elsewhere.
51 Brieﬂy, using
sodium pentobarbital anesthesia (60mg/kg, intraperitoneally (i.p.)), both common
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Cell Death and Diseasecarotid arteries (CCAs) of rats were dissected free, and the incision was closed.
Immediately after this procedure,both vertebral arteries(VAs) between the ﬁrst and
second cervical vertebrae were exposed and electro-cauterized completely using a
bipolar cauterizer under an operating microscope (SZH-ILLB, Olympus, Tokyo,
Japan). After 24h, the common arteries were occluded with aneurysm clips for
20min. The clips were then removed, and blood ﬂow though the arteries was
conﬁrmed before the wound was sutured. Rectal temperature was continually
monitored and maintained at B371C using a heating pad until the animal had fully
recovered from anesthesia. Sham operation (control) groups had a permanent
bilateral occlusion of VAs (2VO rats) that was carried out in the same manner as in
4VO rats, except that the CCAs were not occluded. All rats were allowed to survive
for 8 days after the onset of cerebral ischemia.
Preparation of the focal cerebral ischemia model. Focal cerebral
ischemia was induced by MCAO for 60min using the intraluminal ﬁlament insertion
technique, as described previously.
52 All mice were anesthetized with 2%
halothane, and were then maintained with 1% halothane in 70% N2O and 30%
O2 using a vaporizer. Brieﬂy, a poly-L-lysine (0.1% per weight volume)-coated nylon
monoﬁlamentthread(3/0Gwiththetipheatbluntedtoadiameterof0.104mm)was
inserted through the external carotid artery and advanced into the internal carotid
artery to occlude the origin of the MCA (B12mm). Adequacy of vascular occlusion
and reperfusion was monitored in the front parietal cortex of the occluded side by
PerimedPF5050(Perimed,Jarfalla,Sweden)multichannellaserDopplerﬂowmetry.
Body and head temperatures were monitored and controlled at 37±0.51C using a
homeothermic blanket and water pads. Arterial blood pressure and gases were
monitored through a femoral catheter. After 60min of occlusion, the ﬁlament was
withdrawn to allow for reperfusion, and animals recovered from anesthesia and
survived for 24h. Sham-operated animals were treated identically, except that
MCAs were not occluded after the neck incision.
Drug administration. Animals subjected to cerebral ischemia treatment or
sham operation were blinded to drug-treated groups. e-Baifuzi was diluted in 0.9%
salinetoaﬁnalconcentrationof1.0%ethanolthatwasusedasvehiclecontrol.CTX,
aB K Ca channel blocker, was dissolved in 0.9% saline and injected into the
cereboventricle (i.c.v.). e-Baifuzi was administered i.p. For i.c.v. implantation, mice
were anesthetized with ketamine (80mg/kg i.p.). A guide cannula (4mm length,
23G) aimed above the left lateral ventricle was implanted and anchored to the skull
with four stainless steel screws and dental cement. The guide cannula was
implanted above the rostral ventricle so as to not lesion the hippocampus. The drug
was prepared freshly on the day of the experiment and injected using a stepper-
motorized microsyringe (Stoelting, Wood Dale, IL, USA) at a rate of 0.5ml/min (ﬁnal
volume¼3ml per mouse). Control mice were given an equal volume of vehicle.
Histological examination after 4VO. On the eighth day post-4VO, all
animals were deeply anesthetized with pentobarbital (50mg/kg) and were perfused
transcardially with ice-cold phosphate-buffered saline (PBS), followed by 4% ice-
cold phosphate-buffered paraformaldehyde. The brains were removed, postﬁxed in
the same ﬁxative for 24h and then processed for parafﬁn embedding. Coronal
sections(4mm in thickness)includingthe dorsalhippocampus were cut andstained
with toluidine blue. All slide preparations were randomly coded so that observers
were blind to the experimental condition. Healthy CA1 pyramidal neurons, showing
a round cell body with a plainly stained nucleus, were counted by eye using a
conventional light microscope (PD70) with a 100 objective. The number of
surviving pyramidal neurons per 1mm length along the extent of the CA1 pyramidal
layerwascountedasneuronaldensity(cellspermm)asdescribedelsewhere.
53We
also conducted supplemental examinations on several slices stained with trypan
blue that stains dead cells, and obtained results that were essentially the same as
that determined by eye with the toluidine blue-stained slices. To exclude the
possibility that alterations in cell density value might be a consequence of changes
in the volume of reference, we used a subset of the sections for volume estimation
of CA1 stratum radiatum using Scion Image software (Scion Corp., Frederick, MD,
USA). Six slices were prepared from the right and left dorsal hippocampus each to
count the number of surviving pyramidal neurons.
Lesion size measurement after MCAO. Using 2,3,5-triphenyltetrazolium
chloride (TTC) staining, we measured the infarct size at 24h of reperfusion, as
described previously.
20 All animals were killed under deep halothane anesthesia,
and the brains were quickly frozen and sliced into thick sections for infarct
measurement. Tissue infarction was identiﬁed by TTC staining in thick (2mm)
coronalsections.Sliceswerephotographed,andimageswerestudiedusingimage-
analysis software (MCID; Imaging Research, St. Catharines, ON, Canada). The
infarct volume in all slices was expressed as a percentage of the contralateral
hemisphere after correcting for edema.
Behavioral analysis. AnimalsweretrainedinthestandardMorriswatermaze
task
54. FortheMorris water mazetask,apool(90cm diameter,45cmheight) made
of black-colored plastic was prepared, and was ﬁlled with water (20±11C) that was
rendered opaque with nontoxic blue paint. Swimming paths were analyzed by a
computer system using a video camera (AXIS-90 Target/2; Neuroscience, Inc.,
Tokyo, Japan). In the hidden-platform test, the platform (7cm in diameter) was
submerged 1cm below the water surface. The ﬁrst day of training began with a free
swim, in which the swim speed was assessed in the absence of the platform, and
then immediately after the free swim, mice were given four training trials per day
over5days,inwhichtheyweregiven90stoswimtothehiddenplatform.Ifamouse
did not ﬁnd the platform in the allotted time, it was placed on the platform for 15s.
The average swim speed (cm/s) and latency (s) to reach the platform were scored
on all trials and analyzed. Data were obtained from groups of 10 mice throughout
the experiments.
Electrophysiological analysis
Slice preparation. Rats were decapitated under deep anesthesia with ethyl
ether.Brainswererapidlyremovedandcoronalbrainslices(400mm)werecutusing
a vibrating microtome (Microslicer DTK 1500, Dousaka EM Co., Kyoto, Japan) in
ice-cold cutting solution composed of (in mM) 94 sucrose, 30 NaCl, 4.5 KCl, 1.0
MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose with pH 7.4. The hippocampal
slices were continuously incubated in artiﬁcial cerebrospinal ﬂuid (ACSF) at
36±11C for more than 60min to allow the slices to recover. ACSF was composed
of (in mM) 124 NaCl, 2 CaCl2, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10
D-glucose. pH was adjusted to 7.4. Both the cutting solution and ACSF were
oxygenated with a gas mixture of 95% O2 and 5% CO2.
Field potential recording. For recordings, the slice was transferred into a
recording chamber and perfused continuously with oxygenated ACSF at a ﬂow rate
of B1ml/min. The experiments were conducted at 30±11C. Brieﬂy, orthodromic
stimuli were delivered using an electrically polished bipolar tungsten electrode that
was placed in the outer third of the molecular stratum of hippocampaldentate gyrus
to stimulate the lateral perforant path. Constant current pulses (0.05Hz) were
supplied by a stimulator (SEN-3301, Nihon Kohden, Tokyo, Japan). EPSP was
recorded from the middle third of the molecular stratum with a 4–5MO resistance
glass microelectrode that was ﬁlled with 0.9% NaCl and connected to a neutralized,
high input-impedance preampliﬁer with a high-pass ﬁlter at 5kHz. The level of test
stimulus was set to evoke B50% of a minimum stimulus intensity that evoked a
saturated EPSP in each slice to avoid possible deprivation of readily releasable
transmitters. Signals were ampliﬁed using a differential AC ampliﬁer (A-M Systems,
model 1700, Seattle, WA, USA). EPSPs were digitized and saved using the
pCLAMP system (Axon Instrument Inc., Foster City, CA, USA). Stability of baseline
recordings was established by delivering single pulses (1 per min, 0.1ms pulse
width at an intensity yielding half-maximal EPSP amplitude for a given slice) for 15–
30min before collection of input/output functions. Baseline synaptic transmission
was assessed by averaging the response to ﬁve pulses (from 0.1 to 1.0mA)
delivered at a rate of 0.05Hz. PPF was examined at a range of IPIs (25–150ms)
and a stimulus intensity of half-maximal for elicitation of EPSP.
Optical recordings. All slices used in optical recording were stained with a
voltage-sensitive dye (RH155 0.2mg/ml, Nippon Kanko Shikiso Kenkyujo,
Okayama, Japan) for 15min, and were kept in a chamber containing oxygenated
ACSF for at least 30min for recovery as described previously.
55 The slices were
then transferred into a recording chamber and placed on the stage of an Olympus
inverted microscope (IMT-2, Nikon, Tokyo, Japan). Test stimulus was set at 50%
maximal stimulus intensity to evoke optical EPSP (op-EPSP) in each slice. Light
from a tungsten-halogen lamp (type JC-24v/200W, Kondo Philips, Tokyo, Japan)
was collimated, and an interference ﬁlter with a transmission maximum at
700±10nm (Olympus Optical, Tokyo, Japan) was used. Changes in light
absorption associated with membrane potential changes were measured using an
opticalrecordingsystemequippedwithahigh-speeddiodecamerawithmetaloxide
(MOS) image sensors (128 128 pixels, each of which receives light from a
25mm 25mm sample area) and a data processing unit (HR Deltaron-1700 Fujix;
Fuji Photo Film, Tokyo, Japan). To minimize bleaching of the dye molecules and
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and the light path to the slice was opened only long enough to measure optical
responses (1–2s). In each trial, a background image recorded for 16ms before
electrical stimulation was stored as a reference image. To analyze the change in
neuronalactivitiesover time at agiven region,data fromeachpixel werestored and
retrieved, and the amplitude of the optical signal (indicated as a percentage change
in optical absorbency) was plotted as a function of time. Signals obtained from six
pixels in str. molecular were averaged. RH155 dye is reported to stain glial cells
preferentially over neuronal cells.
56 Optical recording with the RH155 dye is used to
monitor glial depolarization by the electrogenic glutamate transporter (GLT-1)
uptaking the released glutamate.
57 When AMPA and NMDA receptors are blocked,
a delayeddepolarizing response can be recorded,which is completelyabolishedby
the speciﬁc GLT-1 blocker. Thus, the size of SIGD is considered to reﬂect the
probability of presynaptic glutamate release.
Patch-clamp recordings. Whole-cell currents were measured using a
conventional tight seal whole-cell recording technique at room temperature.
Pipettes had resistances at a range of 2–5MO in recording solution containing
(inmM)145KCl,10EGTA,10HEPES(pH7.3withKOH)andCaCl2adjustedtothe
desired [Ca
2þ]free. The intracellular free Ca
2þ concentration ([Ca
2þ]i) was
0.1mM, if not stated otherwise. The extracellular solution was Hanks’ balanced salt
solution (Sigma, St Louis, MO, USA): 1.3 CaCl2, 0.8 MgSO4, 5.4 KCl, 0.4 KH2PO4,
136.9 NaCl, 0.3 Na2PO4,1 0D-glucose and 4.2 NaHCO3. Compensation for cell
capacitance and series resistance was made automatically using EPC-9 or EPC-10
ampliﬁers; only recordings with stable series resistances p25MO were included in
the study. Currents were ampliﬁed using EPC-9 or EPC-10 patch-clamp ampliﬁers
(HEKA, Lambrecht, Germany), sampled at 2–5kHz and ﬁltered at 1.5–2.9kHz
using a 4-pole low-pass Bessel ﬁlter. Program packages Patchmaster 2.1 and TAC
4.1 (HEKA) were used for data acquisition and analysis. The probability of a single
channelbeing open (Po) was simply calculated from the total time spent in the open
state divided by the total time of recording for the patches containing a single
channel. Continuous recordings of 2000–4000ms were used to estimate Po. When
multiple channels were present in a patch, Po was calculated from the amplitude
histogramasPo¼(1 PC
1/N),wherePCisthefractionofareaundertheclosedstate,
and N is the number of channels.To avoid underestimating the number of channels
inapatchaslessaspossible,thenumberofactivesinglechannelsinthepatchwas
counted at the condition in which the maximum number of channels was observed.
Both e-Baifuzi and Baifuzi-CB activate chick BKCa expressed in CHO cells, as well
as rat BKCa expressed in HEK293 cells, at both the single channel and whole-cell
level. However, for convenience, we present data at the single channel level for
chick BKCa and at the whole-cell level for rat BKCa channels. Both e-Baifuzi and
Baifuzi-CB have low aqueous solubility and were dissolved in 100% dimethyl
sulfoxide (DMSO) as a stock solution and diluted with intracellular or extracellular
solutions to obtain different concentrations as required. The ﬁnal concentration of
DMSO was o0.5% per assay, which had no effect on the BKCa channel.
Plasmid construction and STREX–SBP fusion protein
puriﬁcation. The STREX gene of the chick BKCa channel was ampliﬁed from
pcDNA 3.1-BKCa and subcloned into PQE30(þ) (Novagen, Madison, WI, USA).
The STREX–SBP (streptavidin-binding peptide) fusion protein was constructed
by insertion of a peptide linker (Ser-Gly)5 between the STREX and SBP tag. After
culturing in LB medium containing 0.1mg/ml ampicillin at 371C and 200r.p.m./min,
cells were induced to express the STREX–SBP fusion protein by adding 0.25mM
IPTG until OD600¼0.4. Cells were harvested by centrifugation at 8000r.p.m./min
for 10min, ultrasonicated and centrifuged at 12000r.p.m./min for 30min at 41Ct o
remove the cell fragments. The supernatant was applied to a Ni2þ-NTA column
(Amersham Life Sciences, Buckinghamshire, UK). Gradient imidazole was then
usedtoelutetheprotein.ItspuritywasanalyzedbySDS-PAGE.Thepuriﬁedprotein
was stored in buffer containing 50mM Tris-HCl, pH 8.2, 200mM NaCl, 1mM
1,4-dithiothreitol (DTT) and 20% glycerol at  701C until use.
PLO assay. Five types of lipid-soluble chemicals, including e-Baifuzi, Baifuzi-
CB,POPE(Avanti,Alabama,USA),POPG(sodiumsalt,Avanti)andDPPC(Sigma)
weredilutedandspottedonaHybond-Cextranitrocellulosemembrane(Amersham
Life Sciences) with concentration increased from right to left and air-dried for 1h at
room temperature as described previously.
58 Lipid spots were blocked in buffer 1
(fatty acid-free BSA buffer 40mg/ml, 25mM Tris-HCl pH 7.9, 150mM NaCl) with
gentle shaking for 2h at room temperature and incubated overnight with 9.2mM
STREX–SBP fusion protein in buffer 2 (fatty acid-free BSA 10mg/ml, 25mM Tris-
HClpH 7.9,150mMNaCl)at 41C. Takenasa positivecontrol,thepuriﬁedSTREX–
SBP fusionprotein was also incubated with lipid spots.The membranewas washed
in PBS buffer (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM NaH2PO4,
PH7.4) with 0.05% Tween20, and then incubated in a 1:3000 dilution of
streptavidin-alkaline phosphatase (Promega, Co., Madison, WI, USA) for 1h. The
enzyme was bound to the membrane through interaction between streptavidin and
theSBPtag.Theproteinboundtothelipidswasdetectedwithamixtureof5-bromo-
4-chloro-3-indolyl phosphate and nitroblue tetrazolium (BCIP/NBT, Ameresco,
Solon, OH, USA) as a color development substrate.
Data analysis/statistics. Data were retrieved and processed with the
software Micro cal Origin 6.1 (OriginLab, Northhampton, MA, USA). Group data
were expressed as means±S.E. Experimental results were compared among
groups by ANOVA, followed by Bonferroni’s post hoc test. Statistical analysis was
performed using State7 software (STATA Corporation, TX, USA). Differences at
Po0.05 were considered to be statistically signiﬁcant.
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